Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension (Q34957241)

5 August 2017

title

Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. (English)

1 reference

5 August 2017

1 reference

1 reference

Johannes-Peter Stasch

object named as

Johannes-Peter Stasch

1 reference

5 August 2017

Joachim Mittendorf

1 reference

5 August 2017

Stefan Weigand

1 reference

5 August 2017

Cristina Alonso-Alija

1 reference

5 August 2017

Erwin Bischoff

1 reference

5 August 2017

Achim Feurer

1 reference

5 August 2017

Michael Gerisch

1 reference

5 August 2017

Armin Kern

1 reference

5 August 2017

Andreas Knorr

1 reference

5 August 2017

Dieter Lang

1 reference

5 August 2017

Klaus Muenter

1 reference

5 August 2017

Martin Radtke

1 reference

5 August 2017

Hartmut Schirok

1 reference

5 August 2017

Karl-Heinz Schlemmer

1 reference

5 August 2017

Elke Stahl

1 reference

5 August 2017

Alexander Straub

1 reference

5 August 2017

Frank Wunder

1 reference

5 August 2017

language of work or name

1 reference

1 May 2009

1 reference

5 August 2017

1 reference

5 August 2017

1 reference

5 August 2017

1 reference

5 August 2017

page(s)

853-865

1 reference

YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Cardiovascular effects of modulators of soluble guanylyl cyclase activity.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Pulmonary Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Update in pulmonary hypertension 2005.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Pulmonary Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Nitric oxide and pulmonary arterial pressures in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Efficacy and optimal dose of sildenafil in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

NO-independent stimulators of soluble guanylate cyclase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

NO-independent regulatory site on soluble guanylate cyclase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Dissociation of nitric oxide from soluble guanylate cyclase and heme-nitric oxide/oxygen binding domain constructs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Functional characterization of nitric oxide and YC-1 activation of soluble guanylyl cyclase: structural implication for the YC-1 binding site?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Nitric oxide-dependent allosteric inhibitory role of a second nucleotide binding site in soluble guanylyl cyclase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Functional characterization of two nucleotide-binding sites in soluble guanylate cyclase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

New heterocyclic beta-sheet ligands with peptidic recognition elements

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Synthesis and anticonvulsant activity of N-benzylpyrrolo[2,3-d]-, -pyrazolo[3,4-d]-, and -triazolo[4,5-d]pyrimidines: imidazole ring-modified analogues of 9-(2-fluorobenzyl)-6-(methylamino)-9H-purine

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Efficient Pd-Catalyzed Amination of Heteroaryl Halides

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Design, synthesis, and discovery of 3-piperazinyl-3,4-dihydro-2(1H)-quinolinone derivatives: a novel series of mixed dopamine D2/D4 receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Die Darstellung basisch substituierter Malonsäure-dinitrile

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

A synthesis of adenine; the incorporation of isotopes of nitrogen and carbon

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Bioisosteric prototype design of biaryl imidazolyl and triazolyl competitive histamine H2-receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900014

7 January 2021

Identifiers

DOI

10.1002/CMDC.200900014

1 reference

5 August 2017

1 reference